FDA
-
-
-
-
-
-
-
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
-
-
-
-
-
-
-
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
-
-
-
-
-
-
Cogent Biosciences reports positive APEX trial results for bezuclastinib
-
-
-
-
-
-
-
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial ResultsĀ
-
-
-
-
-
-
-
Cogent Biosciences (COGT) reports positive results from mastocytosis drug trial
-
329,908 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

